60 years of metformin use: a glance at the past and a look to the future

60 years of metformin use: a glance at the past and a look to the future Diabetologia (2017) 60:1561–1565 DOI 10.1007/s00125-017-4343-y EDITORIAL 60 years of metformin use: a glance at the past and a look to the future Sally M. Marshall Published online: 3 August 2017 Springer-Verlag GmbH Germany 2017 Abbreviations diabetes want medication that is effective at reducing blood DPP Diabetes Prevention Program glucose levels, easy to take, preferably has once-daily dosing, DPPOS Diabetes Prevention Program Outcomes Study has no short- or long-term side effects, carries no risk of eGFR Estimated GFR hypoglycaemia, does not cause weight gain and is affordable GLP-1 Glucagon-like peptide-1 worldwide. In addition, the ideal drug would address the un- PCOS Polycystic ovary syndrome derlying pathophysiology of type 2 diabetes and have added SGLT2 Sodium–glucose cotransporter 2 value in terms of reducing non-glycaemic risk factors for, and UKPDS UK Prospective Diabetes Study the incidence of, micro- and macrovascular complications of diabetes. How does metformin match up to these demands? The medication is certainly an effective glucose-lowering agent, generally reducing HbA by approximately 1c This year marks the 60th anniversary of the first clinical use of 10–15 mmol/mol (1.0–1.5%) in type 2 diabetes [4]. metformin for diabetes. From small beginnings (and despite a However, we are beginning to realise that not http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

60 years of metformin use: a glance at the past and a look to the future

Loading next page...
 
/lp/springer_journal/60-years-of-metformin-use-a-glance-at-the-past-and-a-look-to-the-YGFMdjMJea
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Internal Medicine; Metabolic Diseases; Human Physiology
ISSN
0012-186X
eISSN
1432-0428
D.O.I.
10.1007/s00125-017-4343-y
Publisher site
See Article on Publisher Site

Abstract

Diabetologia (2017) 60:1561–1565 DOI 10.1007/s00125-017-4343-y EDITORIAL 60 years of metformin use: a glance at the past and a look to the future Sally M. Marshall Published online: 3 August 2017 Springer-Verlag GmbH Germany 2017 Abbreviations diabetes want medication that is effective at reducing blood DPP Diabetes Prevention Program glucose levels, easy to take, preferably has once-daily dosing, DPPOS Diabetes Prevention Program Outcomes Study has no short- or long-term side effects, carries no risk of eGFR Estimated GFR hypoglycaemia, does not cause weight gain and is affordable GLP-1 Glucagon-like peptide-1 worldwide. In addition, the ideal drug would address the un- PCOS Polycystic ovary syndrome derlying pathophysiology of type 2 diabetes and have added SGLT2 Sodium–glucose cotransporter 2 value in terms of reducing non-glycaemic risk factors for, and UKPDS UK Prospective Diabetes Study the incidence of, micro- and macrovascular complications of diabetes. How does metformin match up to these demands? The medication is certainly an effective glucose-lowering agent, generally reducing HbA by approximately 1c This year marks the 60th anniversary of the first clinical use of 10–15 mmol/mol (1.0–1.5%) in type 2 diabetes [4]. metformin for diabetes. From small beginnings (and despite a However, we are beginning to realise that not

Journal

DiabetologiaSpringer Journals

Published: Aug 3, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off